Asoprisnil
![]() | |
Systematic (IUPAC) name | |
---|---|
rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17- | |
Identifiers | |
CAS Number |
199396-76-4 ![]() |
ATC code | none |
PubChem | CID 9577221 |
IUPHAR/BPS | 2883 |
ChemSpider |
7851660 ![]() |
UNII |
72W09924WP ![]() |
KEGG |
D02996 ![]() |
ChEMBL |
CHEMBL267431 ![]() |
Chemical data | |
Formula | C28H35NO4 |
Molar mass | 449.582 g/mol |
| |
| |
![]() ![]() |
Asoprisnil (J867) is an investigational selective progesterone-receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone-sensitive myomata.[1]
In 2005, phase-III trials were discontinued due to endometrial changes in patients. Whether asoprisnil will be marketed is uncertain.[2]
References
- ↑ DeManno D, Elger W, Garg R; et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
- ↑ Schering Interim Report Q1-3 2005
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.